�Curis, Inc. (NASDAQ: CRIS), a drug development party focused on developing following generation proprietorship targeted medicines for cancer treatment, announced that the first patient role has been treated in a Phase I clinical trial of CUDC-101, a first-in-class low molecule drug candidate that has been designed as an inhibitor of epidermic growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2) and histone deacetylase (HDAC). CUDC-101 has been intentional to simultaneously inhibit kinase activity of EGFR and Her2 patch also meddlesome with other key drivers of the cancer cell signaling network involved in tumor electric cell growth and survival through its HDAC inhibitory body process.
"We are very pleased to be participating in a trial with this promising new drug campaigner," commented Dr. Anthony W. Tolcher, Director of Clinical Research at South Texas Accelerated Research Therapeutics (START), and lead investigator of the CUDC-101 Phase I trial. "This trial aims to build on presymptomatic data suggesting that CUDC-101 may have activity across a all-embracing range of cancer types, particularly those that ar resistant to currently marketed drugs. We look forward to exploring the potency of CUDC-101 in the clinic."
"This is an important milepost for the company as we focus on advancing our targeted small corpuscle drug candidates for malignant neoplastic disease treatment into the clinic," said Curis President and CEO Dan Passeri. "We believe that CUDC-101's compounding of clinically-validated cancer targets in a single agent may present an significant advance in targeted malignant neoplastic disease therapy with respect to efficacy and safety. Moreover, single multi-targeted agents may have potentially significant monetary value advantages over multiple drugs with the same butt profile."
The Phase I trial is designed as an open-label dose escalation study of CUDC-101 in patients with advanced, refractory solid tumors. CUDC-101 will be administered on days one to five of a xIV day bike. The outset patient enrolled in the Phase I study has completed five days of dosing. The primary objectives of the Phase I trial are to appraise the safety and tolerability of escalating doses of the Phase I molecule and to establish the maximum tolerated dose and dose limiting toxicities. Secondary objectives testament be to assess the pharmacokinetics, efficacy and power of CUDC-101 to inhibit HDAC, EGFR and Her2 in this patient population. The study is expected to be conducted at two sites within the United States and to enroll betwixt 18 and 40 patients across various dose-escalating cohorts. Further trial details ar posted at ClinicalTrials.gov.
About Curis' Targeted Cancer Drug Development Programs
The end of Curis' targeted crab drug development programs is to rationally design and develop novel, proprietary little molecules that target one or more than clinically validated targets or pathways known to wreak key roles in the development or maintenance of cancer. By focusing on these validated targets, Curis hopes to reduce risk, time and costs associated with the drug development process. Using its targeted cancer dose development platform, Curis has generated single agent, multi-target small molecules that are being intentional to aggregate HDAC inhibition with crushing of targets that include EGFR, Her2, VEGFR, BCR-Abl/Src, MET, CDK, Aurora, RAF and MEK, with a goal of potentially providing enhanced efficacy over existing drugs. The first developmental candidate selected from this multi-target program is CUDC-101, a first-in-class small molecule designed to inhibit EGFR, Her2 and HDAC. Curis is also using its targeted cancer drug development platform to design single agent, single-targeted drug candidates that it believes give the voltage to reach best-in-class condition among existing single object drugs. The first candidate to be selected from Curis' undivided targeted inhibitors is CUDC-305, an by word of mouth available, synthetic small molecule inhibitor of heat cushion protein 90 (Hsp 90).
About Curis, Inc.
Curis is a drug development company that is committed to leverage its innovative signaling pathway drug technologies to seek to make new targeted small molecule drug candidates for cancer. In expanding its dose development efforts in the field of cancer through its targeted cancer drug development chopine, Curis is building upon its old experiences in targeting signaling pathways for the maturation of next generation targeted cancer therapies. For more information, see Curis' internet site at hypertext transfer protocol://www.curis.com.
Cautionary Statement
This iron release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the expected benefits of CUDC-101, the planned development of drug candidates pursuant to the Company's targeted cancer drug development platform and the Company's plans for its form I trial run of CUDC-101 . The Company may use words such as "believes", "expects", "anticipates", "plans", "seeks", "estimates", "testament", "may" or similar expressions to identify these modern statements. There are important factors that may cause actual results to be materially dissimilar from those indicated by such forward-looking statements including, among other things, risks relating to: the potential for untoward results, delays and/or failures in the Company's targeted cancer drug development program, including without limitation unintentional delays and/or failures in its clinical trial of CUDC-101 and its ongoing preclinical studies of CUDC-305; the success of the Company's coaction with Genentech, including the risks that Genentech whitethorn experience untoward results, delays and/or failures in the Hedgehog pathway antagonist program currently below clinical development and that the Company may take no control over, or foreknowledge of, the advancement of this program; difficulties or delays in obtaining or maintaining required regulatory approvals for products under development both internally and through the Genentech collaborationism; the Company's ability to obtain or maintain necessary intellectual property protection; inauspicious changes in the Company's ability to successfully action its business plan, including the Company's ability to obtain the substantial extra funding required for such execution; unplanned cash requirements and expenditures which, among other things, could shorten the estimated period in which the Company will have hard currency to fund its operations and which could also adversely dissemble the Company's estimated operating expenses for 2008 and beyond; risks relating to the Company's ability to enter into and maintain planned collaborations and maintain its stream collaborations with Genentech; and competitive pressures. The Company also faces other risk factors identified in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and former filings that it periodically makes with the Securities and Exchange Commission.
In addition, whatever forward-looking statements represent the Company's views only as of today and should not be relied upon as representing the views as of any subsequent date. Curis disclaims whatsoever intention or obligation to update whatever of the forward-looking statements after the date of this push release whether as a result of new information, future events or otherwise.
Curis, Inc.
More info
Monday, 1 September 2008
Friday, 22 August 2008
Noah And The Whale Announce North American Tour
Noah And The Whale are place setting their sights on the U.S. by heading out on tour there on in a months time.
The band will play xIII shows during September and October, as they promote debut album 'Peaceful The World Lays Me Down', which was released in their native UK before this week. The album will be in stores on September 16.
Noah and The Whale will play these shows below, some of which are disengage performances (marked with a *)
September Tour Dates:
Brooklyn, NY, Union Pool � 16
New York, NY, Sidewalk Cafe � 18
New York, NY, Mercury Lounge � 19
Boston, MA, TOAD � 20*
Montreal, QC, The Saints � 22*
Toronto, ON, Horseshoe Tavern � 23*
Chicago, IL, TBA � 25
Chicago, IL, Empty Bottle � 26
Seattle, WA, Chop Suey � 29*
Portland, OR, Doug Fir Lounge � 30*
October Tour Dates:
San Francisco, CA, 330 Ritch � 2
Los Angeles, CA, Detour Festival � 4
Los Angeles, CA, Spaceland � 6*
More information
Wednesday, 6 August 2008
Eddy Huntington
Artist: Eddy Huntington
Genre(s):
disco
Other
Discography:
Meet My Friend (Single)
Year: 1987
Tracks: 5
U.S.S.R.
Year:
Tracks: 14
Hey Senorita (Single)
Year:
Tracks: 3
Fragrance Materials Association Assures Safety Of Fragrance Ingredients - No Contrary Evidence In Contested University Of Washington Study
�A written report was released by Anne Steinemann, a researcher at the University of Washington
claiming sweetness ingredients contained in a selection of consumer products are potentially toxic.
The fragrance materials industry has the highest concern for the base hit of its products.
We have a sound four-step safety testing process. RIFM, the Research Institute for Fragrance
Materials (an internationally recognized scientific body), examines multiple endpoints and exposure
for redolence materials bound for habit in consumer products. RIFM's findings are evaluated by the
RIFM Expert Panel (REXPAN), an independent and international group of dermatologists,
pathologists, environmental scientists and toxicologists world Health Organization have no ties to the scent industry.
REXPAN's findings are in turn used by IFRA, the International Fragrance Association, to develop
standards on aroma material usance. The IFRA Standards form the base of the globally accepted
and recognized risk management system for the safe use of fragrance ingredients and are part of the
comprehensive program contained in the IFRA Code of Practice. As a result the IFRA Code of
Practice contains around 150 substances which have been either banned or restricted in their use in
perfume products. All members of the Fragrance Materials Association of the United States (FMA)
ar required, as a condition of rank, to observe the IFRA Code of Practice. The fragrance
industry spends just about $8 1000000 (annually) in joint research on the safety of fragrances, and
much more at the individual company level.
The Steinemann study presents no new information or find analysis. Furthermore, while
Steinemann clearly states the study does not address golf links between exposure to chemicals and
wellness effects, she goes beforehand and makes that assertion anyway. She claims that, simply because
certain chemicals are salute in the analyzed products they pose a health risk to all consumers. This
is hardly sound science, just rather more like watch crystal ball gazing and cannot be compared to the
sound, main four-step safety testing process outlined above which is carried out by the
fragrance industry.
Steinemann says she's concerned about "potential perniciousness" of the chemicals launch in the tested
products. The conception of "potentially" hazardous is so tolerant that it may encompass any naturally
occurring material in department of Commerce. Many chemicals, including body of water, have no harmful effects at low
concentrations, just may be "potentially toxic" at high concentrations. We are sure that, when used in compliance with Standards, the materials which are listed by Steinemann and victimized as perfume
ingredients ar safe and can be used (if desired) with confidence.
The study found 58 unlike volatile organic compounds (VOCs) at levels above a concentration of
300 parts per one thousand million but did not lean the immersion of each chemical. To put this in context, 300
parts per zillion is just above the level of analytical spying for these materials. Ingredients which
sound scary when listed by their chemical names ar materials that occur naturally in everyday
items, often in a lot larger quantities than english hawthorn be used in fragranced products. Some examples
include: alpha-Pinene (pine forests); Acetone (cheddar cheese, apple juice, strawberries); 2-
Butanone (coffee tree, citrus fruit, grapes); Benzaldehyde (white staff of life - at >40,000 ppm, roasted coffee -
at 2,000 ppm, apple juice - at around ccc ppm); Ethanol (blackberries, cauliflower, cherries,
cucumbers); Ethyl acetate( honey, tomatoes, vinegar).
It would be folly to declare the numerous true pine forests liner the west and east coasts toxic or
risky just because they founder off the VOC, alpha-pinene. Even more folly to put a hazard
warning on a tomato which naturally contains 8501 parts per one thousand thousand of benzaldehye. Or fifty-fifty to
expect forests and tomatoes to be tagged with their constituent chemicals. So wherefore does
Steinemann want the fragrance manufacture to mark the very low levels of these same chemicals when
contained in our products, and why does she ascribe that these chemicals ar hazardous when
clearly that is non the guinea pig?
We recognize that a small number of individuals may have sensitivity to certain materials in the
environment, both natural and man-made. People who have such sensibility to consumer
products can choose to avoid using the products. We obedience that right to choose and only ask that
all citizenry - including those wHO choose to use fragranced products - are afforded the like privilege.
Consumers can get information through various consumer products websites such as the Consumer
Specialty Products Association, Soap and Detergent Association, Personal Care Product Council and
other consumer websites. Consumer product companies will answer specific questions about their
end use products, particularly if thither is a health concern. In rick, raw material suppliers will provide
information to their customer companies for consumer questions. Each fragrance provider has a
designated regulative contact wHO will supply dermatologists and other medical professionals with
otherwise individual information to assist in the diagnosis and handling of an individual's personal
situation.
The fragrance manufacture continues to work through a sound independent testing mechanism to ensure
its products persist safe for consumers.
About FMA
The Fragrance Materials Association is a national trade association representing companies engaged
in the issue, invention and manufacture of mixtures of fragrance ingredients for use in a wide variety
of products, including fine fragrances, shampoos, soaps and detergents. FMA's activities are closely
coordinated with those of the Research Institute for Fragrance Materials (RIFM). FMA is a member of
the International Fragrance Association (IFRA) which sets safety standards for our products. In
fulfilling its mission for the industry, FMA interacts with governmental bodies and other organizations
on all levels - state, federal and international. FMA meets the necessarily of today's challenges to the
bouquet industry.
Fragrance Materials Association
More info
claiming sweetness ingredients contained in a selection of consumer products are potentially toxic.
The fragrance materials industry has the highest concern for the base hit of its products.
We have a sound four-step safety testing process. RIFM, the Research Institute for Fragrance
Materials (an internationally recognized scientific body), examines multiple endpoints and exposure
for redolence materials bound for habit in consumer products. RIFM's findings are evaluated by the
RIFM Expert Panel (REXPAN), an independent and international group of dermatologists,
pathologists, environmental scientists and toxicologists world Health Organization have no ties to the scent industry.
REXPAN's findings are in turn used by IFRA, the International Fragrance Association, to develop
standards on aroma material usance. The IFRA Standards form the base of the globally accepted
and recognized risk management system for the safe use of fragrance ingredients and are part of the
comprehensive program contained in the IFRA Code of Practice. As a result the IFRA Code of
Practice contains around 150 substances which have been either banned or restricted in their use in
perfume products. All members of the Fragrance Materials Association of the United States (FMA)
ar required, as a condition of rank, to observe the IFRA Code of Practice. The fragrance
industry spends just about $8 1000000 (annually) in joint research on the safety of fragrances, and
much more at the individual company level.
The Steinemann study presents no new information or find analysis. Furthermore, while
Steinemann clearly states the study does not address golf links between exposure to chemicals and
wellness effects, she goes beforehand and makes that assertion anyway. She claims that, simply because
certain chemicals are salute in the analyzed products they pose a health risk to all consumers. This
is hardly sound science, just rather more like watch crystal ball gazing and cannot be compared to the
sound, main four-step safety testing process outlined above which is carried out by the
fragrance industry.
Steinemann says she's concerned about "potential perniciousness" of the chemicals launch in the tested
products. The conception of "potentially" hazardous is so tolerant that it may encompass any naturally
occurring material in department of Commerce. Many chemicals, including body of water, have no harmful effects at low
concentrations, just may be "potentially toxic" at high concentrations. We are sure that, when used in compliance with Standards, the materials which are listed by Steinemann and victimized as perfume
ingredients ar safe and can be used (if desired) with confidence.
The study found 58 unlike volatile organic compounds (VOCs) at levels above a concentration of
300 parts per one thousand million but did not lean the immersion of each chemical. To put this in context, 300
parts per zillion is just above the level of analytical spying for these materials. Ingredients which
sound scary when listed by their chemical names ar materials that occur naturally in everyday
items, often in a lot larger quantities than english hawthorn be used in fragranced products. Some examples
include: alpha-Pinene (pine forests); Acetone (cheddar cheese, apple juice, strawberries); 2-
Butanone (coffee tree, citrus fruit, grapes); Benzaldehyde (white staff of life - at >40,000 ppm, roasted coffee -
at 2,000 ppm, apple juice - at around ccc ppm); Ethanol (blackberries, cauliflower, cherries,
cucumbers); Ethyl acetate( honey, tomatoes, vinegar).
It would be folly to declare the numerous true pine forests liner the west and east coasts toxic or
risky just because they founder off the VOC, alpha-pinene. Even more folly to put a hazard
warning on a tomato which naturally contains 8501 parts per one thousand thousand of benzaldehye. Or fifty-fifty to
expect forests and tomatoes to be tagged with their constituent chemicals. So wherefore does
Steinemann want the fragrance manufacture to mark the very low levels of these same chemicals when
contained in our products, and why does she ascribe that these chemicals ar hazardous when
clearly that is non the guinea pig?
We recognize that a small number of individuals may have sensitivity to certain materials in the
environment, both natural and man-made. People who have such sensibility to consumer
products can choose to avoid using the products. We obedience that right to choose and only ask that
all citizenry - including those wHO choose to use fragranced products - are afforded the like privilege.
Consumers can get information through various consumer products websites such as the Consumer
Specialty Products Association, Soap and Detergent Association, Personal Care Product Council and
other consumer websites. Consumer product companies will answer specific questions about their
end use products, particularly if thither is a health concern. In rick, raw material suppliers will provide
information to their customer companies for consumer questions. Each fragrance provider has a
designated regulative contact wHO will supply dermatologists and other medical professionals with
otherwise individual information to assist in the diagnosis and handling of an individual's personal
situation.
The fragrance manufacture continues to work through a sound independent testing mechanism to ensure
its products persist safe for consumers.
About FMA
The Fragrance Materials Association is a national trade association representing companies engaged
in the issue, invention and manufacture of mixtures of fragrance ingredients for use in a wide variety
of products, including fine fragrances, shampoos, soaps and detergents. FMA's activities are closely
coordinated with those of the Research Institute for Fragrance Materials (RIFM). FMA is a member of
the International Fragrance Association (IFRA) which sets safety standards for our products. In
fulfilling its mission for the industry, FMA interacts with governmental bodies and other organizations
on all levels - state, federal and international. FMA meets the necessarily of today's challenges to the
bouquet industry.
Fragrance Materials Association
More info
Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For Evicel� Liquid Fibrin Sealant (Human)
�OMRIX Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, proclaimed today that it has received a positive thought for EVICEL� Fibrin Sealant (Human) from the Committee for Medicinal Products for Human Use (CHMP). Omrix is seeking approval to market Evicel in Europe for the improvement of hemostasis in surgery.
CHMP is the scientific committee of the European Medicines Agency (EMEA) and is responsible for reviewing medicinal product applications for tone, safety and efficacy. The CHMP's electropositive opinion for Evicel will now be forwarded to the European Commission for marketing authority, which is expected by the end of the third quarter of 2008 (3Q08). The CHMP's feeling also stated that the approved indication for EVICEL would read as follows, "Evicel is used as supportive handling in operation where standard surgical techniques are deficient, for improvement of hemostasis. Evicel is also indicated as suture support for hemostasis in vascular surgery."
EVICEL is currently marketed in the US by Johnson & Johnson Wound Management, a division of ETHICON, INC., a Johnson & Johnson company, with a worldwide hemostasis in surgery reading.
Upon its anticipated approval, EVICEL will be licenced for marketing in the 27 countries of the European Union, or EU. Per the terms of Omrix and ETHICON's append and statistical distribution agreement, ETHICON has the marketing rights for the EU.
About EVICEL
EVICEL� is an all-human, plasma-derived fibrin sealer currently indicated in the US as an adjunct to haemostasis for role in patients undergoing surgery, when control of bleeding by standard surgical techniques is inefficient or airy. It does not take aprotinin, which has been associated with adverse health effects. EVICEL� is easy to use and readily available for time-sensitive needs in the operating room. The product is sold as a frozen limpid and requires less than one moment preparation time after thawing.
About Omrix Biopharmaceuticals, Inc.
Omrix is a in full integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products. Omrix' biosurgery product contrast includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The Company's inactive immunotherapy product line includes antibody-rich products and cartesian product candidates for the discourse of immune deficiencies, infectious diseases and potential biodefence applications. For more information, please visit http://www.omrix.com.
Safe Harbor Statement
This news vent contains modern statements. Forward-looking statements render the Company's current expectations or forecasts of succeeding events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are non historical facts. Forward-looking statements are depicted object to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the modern statements. The Company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the Company's filings with the Securities and Exchange Commission (SEC), including sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K as filed with the SEC on March 17, 2008, and the Company's most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Unless required by law, the Company undertakes no obligation to publicly update or revise any advanced statement to reflect circumstances or events after the date of this news release.
Omrix Biopharmaceuticals, Inc.
More info
CHMP is the scientific committee of the European Medicines Agency (EMEA) and is responsible for reviewing medicinal product applications for tone, safety and efficacy. The CHMP's electropositive opinion for Evicel will now be forwarded to the European Commission for marketing authority, which is expected by the end of the third quarter of 2008 (3Q08). The CHMP's feeling also stated that the approved indication for EVICEL would read as follows, "Evicel is used as supportive handling in operation where standard surgical techniques are deficient, for improvement of hemostasis. Evicel is also indicated as suture support for hemostasis in vascular surgery."
EVICEL is currently marketed in the US by Johnson & Johnson Wound Management, a division of ETHICON, INC., a Johnson & Johnson company, with a worldwide hemostasis in surgery reading.
Upon its anticipated approval, EVICEL will be licenced for marketing in the 27 countries of the European Union, or EU. Per the terms of Omrix and ETHICON's append and statistical distribution agreement, ETHICON has the marketing rights for the EU.
About EVICEL
EVICEL� is an all-human, plasma-derived fibrin sealer currently indicated in the US as an adjunct to haemostasis for role in patients undergoing surgery, when control of bleeding by standard surgical techniques is inefficient or airy. It does not take aprotinin, which has been associated with adverse health effects. EVICEL� is easy to use and readily available for time-sensitive needs in the operating room. The product is sold as a frozen limpid and requires less than one moment preparation time after thawing.
About Omrix Biopharmaceuticals, Inc.
Omrix is a in full integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products. Omrix' biosurgery product contrast includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The Company's inactive immunotherapy product line includes antibody-rich products and cartesian product candidates for the discourse of immune deficiencies, infectious diseases and potential biodefence applications. For more information, please visit http://www.omrix.com.
Safe Harbor Statement
This news vent contains modern statements. Forward-looking statements render the Company's current expectations or forecasts of succeeding events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are non historical facts. Forward-looking statements are depicted object to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the modern statements. The Company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the Company's filings with the Securities and Exchange Commission (SEC), including sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K as filed with the SEC on March 17, 2008, and the Company's most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Unless required by law, the Company undertakes no obligation to publicly update or revise any advanced statement to reflect circumstances or events after the date of this news release.
Omrix Biopharmaceuticals, Inc.
More info
Friday, 11 July 2008
New Edition - New Edition And New Kids Team Up
Veteran boy bands NEW EDITION and NEW KIDS ON THE BLOCK are to team up to record a new track.
The reformed groups have been brought together by New Kids star Donnie Wahlberg, who initially came up with the idea and co-wrote the tune.
The new song, Full Service, will appear on NKOTB's untitled new album.
However, it won't feature former New Edition star Bobby Brown, who wasn't part of the recording process.
Producer RedOne tells People.com, "It went really smoothly. There were no egos or attitudes. It felt like they'd been friends forever."
The project ends decade-long rumours the two boy bands intensely dislike each other.
See Also
John McLaughlin
Artist: John McLaughlin
Genre(s):
Jazz
Jazz: Fusion
Other
Jazz: Jazz-Rock
Ethnic
Rock
Discography:
Trio of Doom
Year: 2007
Tracks: 7
Industrial Zen
Year: 2006
Tracks: 8
After The Rain
Year: 2005
Tracks: 9
Live In Paris The Heart Of Things
Year: 2000
Tracks: 6
Live In Paris
Year: 2000
Tracks: 6
The Heart Of Things
Year: 1997
Tracks: 6
This Is Jazz 17
Year: 1996
Tracks: 10
The Promise
Year: 1995
Tracks: 11
Promise
Year: 1995
Tracks: 11
Molom - A Legend Of Mongolia
Year: 1995
Tracks: 22
Molom
Year: 1994
Tracks: 22
Tokyo Live
Year: 1993
Tracks: 8
Time Remembered (John McLaughlin Plays Bill Evans)
Year: 1993
Tracks: 11
Plays Bill Evans - Time Remembered
Year: 1993
Tracks: 11
Electric Dreams
Year: 1992
Tracks: 8
Que Alegria
Year: 1991
Tracks: 9
Live In Europe 1991
Year: 1991
Tracks: 7
Mediterranean Concerto
Year: 1990
Tracks: 8
Live At The Royal Festival Hall
Year: 1989
Tracks: 6
Fabrik Hamburg Live
Year: 1987
Tracks: 11
Adventures In Radioland
Year: 1987
Tracks: 10
Adventures In Radio Land
Year: 1987
Tracks: 10
Music Spoken Here
Year: 1983
Tracks: 9
Belo Horizonte
Year: 1981
Tracks: 8
Electric Guitarist
Year: 1979
Tracks: 7
Love Devotion Surrender
Year: 1973
Tracks: 5
My Goals Beyond
Year: 1972
Tracks: 10
Where Fortune Smiles
Year: 1971
Tracks: 5
Devotion
Year: 1970
Tracks: 6
Extrapolation
Year: 1969
Tracks: 10
Remember Shakti
Year:
Tracks: 5
A house identify since the early '70s, John McLaughlin was an innovative spinal fusion guitarist when he light-emitting diode the Mahavishnu Orchestra and continued living up to his reputation as a phenomenal and systematically inquisitive player through the eld. He started on guitar when he was 11 and was ab initio divine by blues and drop players. McLaughlin worked with Alexis Korner, Graham Bond, Ginger Baker, and others in the sixties and played rid jazz with Gunter Hampel for six-spot months. His low gear record album was a classic (1969's Extrapolation) and was followed by an obscurity for the Dawns label with John Surman, a quintet set with Larry Young (Devotion), and My Goals Beyond in 1970 which was half acoustic solos and half jams involving Indian musicians.
In 1969, McLaughlin moved to New York to play with Tony Williams' Lifetime and he appeared on two definitive Miles Davis records: In a Silent Way and Bitches Brew. In 1971, McLaughlin formed the Mahavishnu Orchestra, a very powerful group ofttimes thought of as rock only having the sophisticated improvisations of idle words. After leash influential albums (The Inner Mounting Flame, Birds of Fire, and Between Nothingness and Eternity), the group disbanded in 1973. McLaughlin, world Health Organization recorded a knock-down spiritual album with Carlos Santana that was influenced by John Coltrane, put together a new Mahavishnu Orchestra in 1974 that, contempt the inclusion of Jean-Luc Ponty, failed to hitch on and broke up by 1975. McLaughlin then surprised the music reality by radically shifty directions, shift to acoustic guitar and playing Indian music with his grouping Shakti. They made a strong impact on the reality music panorama (which was in its early childhood) during their threesome age. McLaughlin then went back and forth betwixt galvanizing and acoustic guitars; leading the One Truth Band; playing in trios with Al DiMeola and Paco De Lucia; pop up on some mid-'80s Miles Davis records; forming a ephemeral third version of the Mahavishnu Orchestra (with saxophonist Bill Evans); recording an self-examining tribute to piano player Bill Evans; and, in 1993, touring with a sportive nothingness trio featuring Joey DeFrancesco and drummer Dennis Chambers. Throughout his productive life history John McLaughlin has recorded as a leader for Marmalade, Dawns, Douglas International, Columbia, Warner Bros., and Verve.
Nas And Soulja Boy Land Sneaker Deals
Rappers NAS and SOULJA BOY have just signed new sneaker deals.
Nas and sports brand Fila have just entered into a new one-year partnership, while Soulja Boy has signed a multi-year footwear and apparel contract with Yums Shoes.
Fila will back Nas' upcoming tour in support of his untitled album, as part of his deal. In return, the MC will wear Fila products and co-create an 1980s-inspired clothing line, according to Billboard.com.
He says, "My best friend Will and I loved Fila. It represented prestige and everything that was cool to us. When Will passed, we buried him in a black Fila sweat suit, so doing a deal with them has a lot of significance for me."
Meanwhile, Soulja Boy is to release his first shoe later this year (08) - on the back of his new album and cartoon.
He will team up with graffiti artist and designer Tex to create the new sneaker.
Nas and sports brand Fila have just entered into a new one-year partnership, while Soulja Boy has signed a multi-year footwear and apparel contract with Yums Shoes.
Fila will back Nas' upcoming tour in support of his untitled album, as part of his deal. In return, the MC will wear Fila products and co-create an 1980s-inspired clothing line, according to Billboard.com.
He says, "My best friend Will and I loved Fila. It represented prestige and everything that was cool to us. When Will passed, we buried him in a black Fila sweat suit, so doing a deal with them has a lot of significance for me."
Meanwhile, Soulja Boy is to release his first shoe later this year (08) - on the back of his new album and cartoon.
He will team up with graffiti artist and designer Tex to create the new sneaker.
Rediscovered Goya sketches sell for millions at London auction
LONDON - Three sketches by Goya presumed lost for 130 years have sold for a total of about $8 million.
Christie's says the sketches first went up for auction in Paris in 1877 and were presumed lost until a private Swiss collector contacted the auction house about them.
One sketch titled "They go down quarrelling" - which depicts four women fighting as they fall through the air - sold in London for about $4.6 million.
The sketches come from the private notebooks of Francisco Jose de Goya y Lucientes. During the last three decades of his life, the Spanish artist used the notebooks to draw people in various moods and situations.
Goya died in 1828.
See Also
Bad Livers
Artist: Bad Livers
Genre(s):
Other
Discography:
Dust on the Bible
Year: 1994
Tracks: 11
The clubs of Austin, TX, proved to be fat ground in the 1990s for bands with eclecticist musical influences, only the Bad Livers whitethorn possess been the least-categorizable ensemble of all. The trio's recorded songs ran the gamut from traditional folk music and blue grass to blues, early rock & revolve, punk rock rock-and-roll, and finally even trance music. At the altitude of their long touring career it was possible to hear music by the Carter Family, Iggy Pop, Monk, Mississippi John Hurt, the Misfits, and Slayer, all in the course of one concert congeal. They tapped into a base of music fans wHO could apprise a mongrelized euphony, only the by and by stages of their career showed that "Americana" could be a musical category as constraining as whatever other; the band's increasingly experimental mind-set resonated only intermittently with the preferences of fans of traditional music. The Bad Livers' instrumentation was unique inside the pop/rock realm: lead isaac Merrit Singer Danny Barnes played banjo, guitar, and resonator guitar; Mark Rubin played bass voice and bass horn; and in later 1996 the two were linked by Bob Grant on mandolin, guitar, and tenor banjo. Grant replaced Ralph White, wHO played fiddle and Cajun and Mexican accordion with the triplet.
Both Rubin and Barnes grew up with bluegrass music, and that genre label was as liable for the Bad Livers as was any other. Rubin, elevated in rural Oklahoma, began performing sousaphone as a child and continued his studies into senior high school day, when he likewise began playing sea bass. Rubin as well heard klezmer music in his juvenility, and the soundprint of the klezmer banding would turn audible in the music of the Bad Livers. The mathematical group was formed in 1990, correct after Rubin had attended the New Music Seminar in New York and was divine to put together his possess banding; it consolidated with an ad hoc Danny Barnes Trio, which actually consisted of Barnes plus whatever other musicians he was able-bodied to raise on the sound on whatsoever given evening.
The Bad Livers gained widespread attention from Austin clubgoers in 1991 and became the star of the SXSW euphony conference the following year. They signed with the Chicago-based Touch & Go tag, cathartic Delusions of Banjer (1992) and Horses in the Mines (1994). Another recording, Dust on the Bible, was originally sold on cassette at the trio's live shows and was later issued on CD by Touch & Go under its Quarterstick depression; it was a collection of bluegrass-gospel standards that showed that the group could spiel it straight when they so desired. The Bad Livers touched to the North Carolina-based Sugar Hill tag for Hogs on the Highway (1997) and 1998's Diligence and Thrift, the latter album produced by longtime Texas euphony gadfly Lloyd Maines. Each subsequent expiration broadened the trio's musical range, and Blood and Mood, which appeared in early 2000, was an unclassifiable mixed bag of bluegrass, punk, sampling of various kinds, and other electronic techniques. The record album was alternately hailed as a masterpiece and denounced as the last step in a long perfidy of traditional bluegrass; the group's web site drily noted that it was "to date the worst merchandising title in the catalogue." By that time Barnes and Rubin had both become involved with solo projects of their possess; Rubin was the euphony supervisor for Richard Linklater's film The Newton Boys, and Barnes, wHO had stirred to Washington state, had composed music for the Seattle Symphony Orchestra. After Blood and Mood, though the Bad Livers ne'er formally dissolved, the private members' solo projects took precedency. Barnes released several left-of-center banjo albums passably redolent of the Bad Livers' early real, while Rubin remained a secureness of the Austin live-music and recording scene.
Carpe Diem
Artist: Carpe Diem
Genre(s):
Other
Discography:
En Regardant Passer Le Temps
Year: 1975
Tracks: 4
Robert De Niro - De Niro Smith Attend Mandelas Birthday Dinner
Charles Mingus
Artist: Charles Mingus
Genre(s):
Jazz
Discography:
Plays It Cool
Year: 2000
Tracks: 7
Pithecanthropus Erectus: 1955-1957
Year: 1999
Tracks: 9
Paris 1964 Vol.1
Year: 1999
Tracks: 4
Mingus Ah Um
Year: 1999
Tracks: 12
Tonight at Noon
Year: 1998
Tracks: 5
In a Soulful Mood
Year: 1996
Tracks: 8
Paris 1964 Vol.2
Year: 1995
Tracks: 2
Town Hall Concert
Year: 1991
Tracks: 2
Three or Four Shades of Blues
Year: 1990
Tracks: 5
Epitaph CD2
Year: 1990
Tracks: 9
Epitaph CD1
Year: 1990
Tracks: 10
Cumbia and Jazz Fusion
Year: 1978
Tracks: 4
Lionel Hampton Presents Charles Mingus
Year: 1977
Tracks: 10
Changes Two
Year: 1975
Tracks: 5
Changes One
Year: 1975
Tracks: 4
Let My Children Hear Music
Year: 1972
Tracks: 7
The Great Paris Concert (cd2)
Year: 1964
Tracks: 3
The Great Paris Concert (cd1)
Year: 1964
Tracks: 4
The Great Concert (Paris 1964)
Year: 1964
Tracks: 7
Mingus in Europe, Vol. 2
Year: 1964
Tracks: 5
Meditation
Year: 1964
Tracks: 4
The Black Saint and the Sinner Lady
Year: 1963
Tracks: 4
Mingus Plays Piano
Year: 1963
Tracks: 11
Mingus Mingus Mingus Mingus Mingus
Year: 1963
Tracks: 8
The Complete Town Hall Concert
Year: 1962
Tracks: 12
Oh Yeah: Remastered
Year: 1961
Tracks: 10
Ken Burns Jazz Series: Charles Mingus
Year:
Tracks: 9
Irascible, demanding, bullying, and probably a genius, Charles Mingus cut himself a uniquely iconoclastic itinerary through jazz in the middle of the 20th c, creating a legacy that became universally lauded but after he was no thirster around to hemipterous insect people. As a bassist, he knew few peers, blame with a powerful tone and pulsating sense of rhythm method of birth control, capable of elevating the instrument into the front demarcation of a band. But had he been barely a string player, few would know his list today. Rather, he was the superlative bass-playing leader/composer jazz has ever so known, one world Health Organization always kept his ears and fingers on the beat, spirit, spontaneity, and savage expressive ability of jazz.
Intensely ambitious yet much earthy in expression, simultaneously radical and deeply traditional, Mingus' music took elements from everything he had experient -- from gospel and blues through New Orleans jazz, swing, boP, Latin music, mod classical medicine, even the jazz van. His standard was Duke Ellington, merely Mingus took the sonic blend and harmonies of Ellingtonia often further, throwing in scratchy dissonances and sharp changes in m and tempo, introducing hugely exhilarating accelerations that generated a momentum of their have. While his early works were written prohibited in a authoritative fashion, by the mid-'50s, he had worked knocked out a new way of getting his unconventional visions crosswise, dictating the parts to his musicians spell allowing plentitude of room for the players' have musical personalities and ideas. He was besides a formidable piano player, full subject of pickings that role in a group -- which he did in his 1961-62 bands, hiring some other bassist to replete in for him.
Along the means, Mingus made a band of enemies, causation sometimes violent confrontations on and off the outdoor stage. A great man physically, he used his majority as a weapon of deterrence, and he was non to a higher place halting concerts to cud out neglectful audiences or errant sidemen, even cashiering a player now and and so on the daub. At one of his concerts in Philadelphia -- and a memorial to a dead co-worker at that -- he stony-broke up the demonstrate by slamming the piano lid down, closely shattering his pianist's hands, and then punched trombone player Jimmy Knepper in the backtalk. For a savage physical portraiture of the emotions that seethed within him, check out the photograph on the cover of Duke Ellington's Money Jungle; Mingus looks as if he is about to vote out individual. But he could besides be a gentle giant as his moods permitted, and that quality tin can be felt in some of his music.
Mingus felt the lash of racial prepossess identical intensely -- which, combined with the frustrations of making it in the music business on his own damage, establish its release in music. Indeed, some of his flaky titles were political in nature, such as Fables of Faubus (referring to the Arkansas governor world Health Organization tried to preserve Little Rock schools segregated), "Oh Lord, Don't Let Them Drop That Atomic Bomb on Me" or "Remember Rockefeller at Attica." But he could besides be wildly humourous, the to the highest degree notorious model organism "If Charlie Parker Was a Gunslinger, There'd Be a Whole Lot of Dead Copycats" (by and by telescoped to "Gunslinging Bird").
Born in a Nogales Army camp, Mingus was shortly thenceforth taken to the Watts territory of Los Angeles, where he grew up. The first music he heard was that of the church service -- the only music his stepmother allowed about the household -- only one day, disdain the threat of penalisation, he tuned in Duke Ellington's "Orient St. Louis Toodle-Oo" on his father's crystal set, his first exposure to jazz. He time-tested to memorise the trombone at sextuplet and then the violoncello, just he became fed up with incompetent teachers and terminated up on the double bass by the time he reached high schooling. His early teachers were Red Callender and an ex-New York Philharmonic bassist named Herman Rheinschagen, and he as well studied composition with Lloyd Reese. A proto-third stream authorship written by Mingus in 1940-41, "Half-staff Inhibition" (recorded in 1960), reveals an extraordinary timbral resource for a adolescent.
As a sea bass prognostic, Mingus performed with Kid Ory in Barney Bigard's mathematical group in 1942 and went on the route with Louis Armstrong the next twelvemonth. He would gravitate toward the R&B side of the route later in the '40s, running with the Lionel Hampton band in 1947-48, support R&B and jazz performers, and leading ensembles in respective idioms under the bring up Baron Von Mingus. He began to attract real national attention as a bassist for Red Norvo's trio with Tal Farlow in 1950-51, and after going that mathematical group, he moved to New York and began working with several astral wind performers, including Billy Taylor, Stan Getz and Art Tatum. He was the bassist in the famed 1953 Massey Hall concert in Toronto with Charlie Parker, Dizzy Gillespie, Bud Powell and Max Roach, and he in short united his idol Ellington, where he had the dubious distinction of being the only man Duke ever so personally fired from his band.
Round this time, Mingus time-tested to cook himself into a rallying point for the jazz community. He founded Debut Records in partnership with his then-wife Celia and Roach in 1952, eyesight to it that the label recorded a wide-eyed variety of jazz from bop to experimental music until its demise in 1957. Among Debut's nigh notable releases were the Massey Hall concert, an record album by Miles Davis, and several Mingus sessions that traced the development of his ideas. He as well contributed composed whole works to the Jazz Composers' Workshop from 1953 to 1955, and later in '55, he founded his have Jazz Workshop repertory mathematical group that base him moving away from strict notation toward his looser, set mode of composing.
By 1956, with the liberation of Genus Pithecanthropus Erectus (Atlantic Ocean), Mingus had intelligibly base himself as a composer and leader, creating pulsating, ever-shifting compendiums of jazz's past and give, spirit his way into the free jazz of the future. For the future decennary, he would stream away an extraordinary torso of work for several labels, including key albums like The Clown, New Tijuana Moods, Mingus Ah Um, Vapours and Roots and Oh Yeah; standards like "Good-bye Pork Pie Hat," "Better Git It in Your Soul," "Haitian Fight Song" and "Wednesday Night Prayer Meeting," and extended works like Meditations on Integration and Epitaph. Through ensembles ranging in sizing from a quartette to an 11-piece big dance orchestra, a procession of celebrated sidemen like Eric Dolphy, Jackie McLean, J.R. Monterose, Jimmy Knepper, Roland Kirk, Booker Ervin, and John Handy would go past, with Mingus' dominating bass and volatile personality push his musicians farther than some of them might make liked to go. The groups with the great Dolphy (heard live on Mingus at Antibes) in the early '60s might have been his to the highest degree dynamic, and The Black Saint and the Sinner Lady (1963), an extended concert dance for heavy band that captures the anguished/joyful split Mingus personality in full, passionately wild cry out -- may be his masterpiece.
Even so, Mingus' obsessive efforts to release himself from the economic hazards and theft of the music business sector intimately undermined his sanity in the 1960s (so, some of the line drive notes for The Black Saint album were written by his psychologist, Dr. Edmund Pollock). He tried to compete with the Newport festivals by organizing his have Jazz Artists Guild in 1960 that purported to give musicians more than control o'er their work, but that collapsed with the by-now-routine gall that accompanied so many Mingus ventures. A fatal, self-presented New York Town Hall concert in 1962; some other, shorter-lived recording venture, Charles Mingus Records, in 1964-65; the nonstarter to find a publishing house for his autobiography Beneath the Underdog, and other setbacks stone-broke his bank business relationship and at last his spirit. He quit music almost completely from 1966 until 1969, resuming performances in June 1969 only because he desperately needful money.
Fiscal angels in the forms of a Guggenheim Fellowship in typography, the publication of Beneath the Underdog in 1971, and the purchase of his Debut masters by Fantasy boosted Mingus' john Barleycorn, and a young stimulating Columbia album Let My Children Hear Music pierce him back up into public attending. By 1974, he had formed a young thomas Young quintette, anchored by his loyal drummer Dannie Richmond and featuring Jack Walrath, Don Pullen and George Adams, and more compositions came away, including the massive, kaleidoscopical, Colombian-based "Cumbia and Jazz Fusion" that began its life as a film account.
Respect was growing, but sentence, regrettably, was running out, for in fall 1977, Mingus was diagnosed with amyotrophic lateral induration (Lou Gehrig's disease), and by the following year, he was unable to play the basso. Though confined to a wheelchair, he all the same carried on, leading recording roger Sessions, and receiving honors at a White House concert on June 18, 1978. His last design was a quislingism, Mingus with folk-rock vocalizer Joni Mitchell, world Health Organization wrote lyrics to Mingus' music and included samples of Mingus' articulation on the record.
Since his demise, Mingus' importance and fame increased unco, thanks in large portion to the compulsive efforts of Sue Mingus, his widow. A posthumous repertory grouping, Mingus Dynasty, was formed nearly like a shot later his death, and that conception was expanded in 1991 into the exciting Mingus Big Band, which has resurrected many of Mingus' most challenging lashings. Epitaph was finally reconstructed, performed and recorded in 1989 to general clap, and several box seat sets of portions of Mingus' yield feature been issued by Rhino/Atlantic, Mosaic and Fantasy. Beyond re-creations, the Mingus influence can be heard on Branford Marsalis' early Scenes in the City album, and specially in the heavy band writing of his comrade Wynton. The Mingus blend of wildly colourful eclectic method solidly rooted in jazz history should serve his legacy well in a future more and more populated by edward Young conservatives world Health Organization want to pay their respects to custom and try something different.
Celeb Shred-Fest!
Subscribe to:
Posts (Atom)